Lilly Forteo
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Firm anticipates a fourth quarter launch for the osteoporosis agent. The parathyroid hormone NDA was filed in late 2000 and is expected to receive a standard revie